Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch

JonesResearch analyst Debanjana Chatterjee raised the firm’s price target on Armata Pharmaceuticals (ARMP) to $20 from $15 and keeps a Buy rating on the shares. After speaking with key opinion leaders, the firm believes Armata’s AP-SA02 is a “potentially paradigm-shifting” front-line therapy. If AP-SA02 materially shortens inpatient days, hospital costs will decline while reimbursement amount remains unchanged, the analyst tells investors in a research note.